D027 E-Portfolio: Advanced Pathopharmacological Foundations
Student Name
Western Governors University
D027 Advanced Pathopharmacological Foundations
Prof. Name
Date
D027 E-Portfolio: Advanced Pathopharmacological Foundations
Instructions
To fulfill the requirements of the course, completion of the Clinical Practice Experience (CPE) Record is mandatory. You can access the CPE Record under the “Supporting Documents” section within your Assessment Task Overview, where all necessary deliverables are outlined. These deliverables should be integrated into your e-portfolio.
Written reflections and submissions may be entered directly into this template. Additionally, you can embed previously created Word or PDF documents by following these steps:
- Position the cursor where the document should appear.
- Click Insert, then select the arrow beside Object.
- Choose Text from File.
- Locate and double-click the desired file.
- Repeat as necessary for additional documents.
1a. CPE Schedule Table
This table is designed to assist with time management and workload organization. Please copy it into your e-portfolio and complete it by adding estimated times and target completion dates.
| Required CPE Activity (Deliverable) | Estimated Time | Anticipated Completion Date |
|---|---|---|
| CPE Schedule Table (Phase 1) | 30 minutes | 08/31/24 |
| Feedback and Synthesis Improvement Plan (Phase 1) | 2 hours | 09/01/24 |
| GoReact Video (Phase 1) | 1 hour | 09/01/24 |
| Peer Responses (Phase 1) | 30 minutes | 09/01/24 |
| Reflection Summary (Phase 1) | 30 minutes | 09/01/24 |
| CPE Schedule Table (Phase 2) | 30 minutes | 09/02/24 |
| Feedback and Synthesis Improvement Plan (Phase 2) | 2 hours | 09/02/24 |
| GoReact Video (Phase 2) | 1 hour | 09/04/24 |
| Peer Responses (Phase 2) | 30 minutes | 09/04/24 |
| Reflection Summary (Phase 2) | 30 minutes | 09/04/24 |
| CPE Schedule Table (Phase 3) | 30 minutes | 09/06/24 |
| Feedback and Synthesis Improvement Plan (Phase 3) | 2 hours | 09/06/24 |
| Feedback and Synthesis Improvement Treatment Plan (Phase 3) | 2 hours | 09/06/24 |
| GoReact Video (Phase 3) | 1 hour | 09/09/24 |
| Peer Responses (Phase 3) | 30 minutes | 09/07/24 |
| Reflection Summary (Phase 3) | 30 minutes | 09/07/24 |
1b. Feedback and Synthesis Improvement Plan
What is Alzheimer’s Disease?
Alzheimer’s disease is a progressive, irreversible neurodegenerative condition primarily affecting cognitive functions and memory. It begins with mild memory loss and gradually deteriorates into an inability to perform routine tasks. This degeneration results from neuronal death causing brain atrophy. According to the Centers for Disease Control and Prevention (CDC), Alzheimer’s ranks among the top 10 leading causes of death in the United States and is the foremost cause of dementia among older adults (Kumar et al., 2024).
What are the Pathophysiological Features of Alzheimer’s Disease?
Alzheimer’s disease pathology is distinguished by two hallmark features: neuritic plaques and neurofibrillary tangles.
- Neuritic Plaques: These are extracellular deposits mainly composed of amyloid beta peptides, surrounded by swollen neuronal endings. They predominantly accumulate within the cortical gray matter, forming complex, multifocal structures.
- Neurofibrillary Tangles: These intracellular inclusions consist of misfolded tau proteins that normally stabilize neuronal microtubules. In Alzheimer’s, tau proteins become abnormally folded, aggregate, and disrupt intracellular transport, leading to neuronal dysfunction. The tangles initially form in the hippocampus—critical for memory—and spread to other cerebral cortical regions as the disease progresses (Kumar et al., 2024).
What Are the Clinical Manifestations of Alzheimer’s Disease?
Alzheimer’s symptoms develop progressively and can be categorized into stages:
- Early Stage: Memory impairment, word-finding difficulties, spatial disorientation, and poor judgment.
- Moderate Stage: Increased confusion, personality alterations, disorientation, and behavioral disturbances.
- Severe Stage: Inability to perform self-care, swallowing problems, and a high risk of complications like aspiration pneumonia, which is a leading cause of mortality in advanced Alzheimer’s (National Institute on Aging [NIA], 2022a).
How Is Alzheimer’s Disease Diagnosed?
Diagnosis is comprehensive and includes:
- Clinical evaluations of cognition, daily functioning, and behavioral symptoms.
- Neuropsychological testing to assess memory, language, attention, and problem-solving.
- Laboratory workups, including urinalysis, to exclude other causes.
- Brain imaging via CT, MRI, or PET scans to detect brain atrophy and amyloid deposits (NIA, 2022b).
2b. Feedback and Synthesis Improvement Plan
What is Heart Disease?
Cardiovascular disease (CVD) is the leading global cause of mortality and encompasses conditions such as coronary artery disease, cerebrovascular disease, peripheral artery disease, and aortic atherosclerosis. The fundamental issue is reduced myocardial blood flow, resulting in ischemia and symptoms like angina or myocardial infarction (Lopez, 2023).
What Is the Pathophysiology of Heart Disease?
The primary pathological process in heart disease is atherosclerosis, characterized by the gradual buildup of lipid deposits, inflammatory cells, and fibrous tissue within arterial walls. This process leads to narrowing (stenosis) and reduced blood flow. Atherosclerosis starts early in life and progresses due to lipid accumulation, immune responses, and endothelial cell dysfunction (Lopez, 2023).
What Are the Clinical Manifestations?
| Symptom | Description |
|---|---|
| Chest pain | Angina caused by myocardial ischemia |
| Shortness of breath | Due to decreased cardiac output |
| Coughing | May indicate fluid accumulation |
| Swelling (legs, feet) | Peripheral edema from heart failure |
| Fatigue | Reduced oxygen supply to tissues |
| Palpitations | Arrhythmias or irregular heartbeats |
How Is Heart Disease Diagnosed?
| Diagnostic Test | Purpose |
|---|---|
| Electrocardiogram (ECG) | Detect cardiac rhythm abnormalities and ischemia |
| Echocardiogram | Visualize heart structure and function |
| Blood tests | Identify cardiac injury biomarkers |
| Chest X-ray | Assess heart size and lung conditions |
| Stress test | Evaluate cardiac function under exertion |
What Are Common Treatments and Lifestyle Changes?
Treatment often involves medications such as beta-blockers, diuretics, statins, aspirin, and anticoagulants. Essential lifestyle modifications include balanced nutrition, regular physical activity, stress management, weight control, smoking cessation, and monitoring blood pressure and cholesterol levels (Lopez, 2023).
3b. Chronic Obstructive Pulmonary Disease (COPD) Synthesis
Patient Case Overview
Ms. O’Connor, aged 55, presents with worsening COPD symptoms, including bronchospasms, fatigue, and productive cough with rusty sputum. Despite using nicotine replacement therapies, she smokes 3 to 5 cigarettes daily since age 15. She reports no allergies, and spirometry reveals an FEV1 of 1.37L. Family history includes a father who succumbed to a heart attack and a mother who died from smoking-related pneumonia. She has gained 30 pounds over the last two years.
What Is the Pathophysiology of COPD?
COPD arises from chronic airway inflammation caused by prolonged exposure to harmful particles or gases, predominantly tobacco smoke. This inflammation causes airway narrowing, loss of lung elasticity, excessive mucus production, and airflow obstruction. Thickened airway walls contribute to air trapping and lung hyperinflation, impairing respiratory function (Agarwal, 2023).
What Are the Signs and Symptoms?
| Sign/Symptom | Description |
|---|---|
| Chronic cough | Persistent and productive |
| Increased mucus | Excessive sputum production |
| Dyspnea | Shortness of breath |
| Pursed-lip breathing | Technique to control airflow |
| Wheezing | Audible airway obstruction |
| Muscle atrophy | Loss of muscle mass due to inactivity |
| Barrel chest | Enlarged chest diameter from hyperinflation |
| Cyanosis | Bluish discoloration due to low oxygen |
| Finger clubbing | Nail deformity linked to chronic hypoxia |
How Is COPD Diagnosed?
Diagnosis is based on clinical evaluation, spirometry and pulmonary function tests, imaging such as chest X-rays and CT scans, arterial blood gases (ABG) analysis, and alpha-1 antitrypsin deficiency screening when indicated (Agarwal, 2023).
What Are Common Treatments?
| Treatment Type | Examples and Purpose |
|---|---|
| Bronchodilators | Short-acting (e.g., albuterol), long-acting (e.g., tiotropium) to relax airway muscles |
| Inhaled corticosteroids | Reduce airway inflammation |
| Smoking cessation aids | Medications like bupropion to support quitting smoking |
| Vaccinations | Annual flu and pneumonia vaccines |
| Pulmonary rehabilitation | Enhances exercise capacity and symptom management |
What Are Possible Side Effects of Medications?
| Medication | Potential Side Effects |
|---|---|
| Bronchodilators | Tremors, anxiety, increased heart rate, headaches |
| Inhaled corticosteroids | Hoarseness, oral thrush |
| Bupropion | Insomnia, dry mouth, headaches, tremors, sweating |
Reflection Summaries
Phase 1 Reflection
My choice to focus on Alzheimer’s disease was inspired by personal experience with a family member affected by it. My research illuminated the disease’s core pathological features: neuritic plaques composed of amyloid-beta and neurofibrillary tangles consisting of tau proteins. Feedback from an intensivist pointed out that my initial synthesis was too intricate, leading me to simplify and clarify the content for better understanding.
Phase 2 Reflection
Heart disease was the subject of Phase 2 to refresh my clinical knowledge. While researching, I encountered extensive information but found balancing depth and clarity challenging. The feedback I received emphasized the importance of concise and clear presentation, which I incorporated to improve the synthesis.
Phase 3 Reflection
In Phase 3, I concentrated on Ms. O’Connor’s case with COPD. This interactive assessment enabled me to develop a comprehensive treatment plan that integrated pharmacological therapy with lifestyle advice. Patient education on medication side effects and adherence was essential. The main challenges involved organizing subjective and objective data accurately and managing documentation within system limitations.
References
Agarwal, A. K. (2023, August 7). Chronic obstructive pulmonary disease. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK559281/
Kumar, A., Sidhu, J., Lui, F., et al. (2024). Alzheimer Disease. In StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK499922/
Lopez, E. O. (2023, August 22). Cardiovascular disease. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK535419/
National Institute on Aging (NIA). (2022a). What are the signs of Alzheimer’s disease? https://www.nia.nih.gov/health/alzheimerssymptoms-and-diagnosis/what-are-signs-alzheimers-disease
National Institute on Aging (NIA). (2022b, December). How is Alzheimer’s disease diagnosed? https://www.nia.nih.gov/health/alzheimerssymptoms-and-diagnosis/how-alzheimers-disease-diagnosed
American Lung Association. (2024b, May). Understanding your COPD medications. https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd/treating/copd-medications